The positive and negative syndrome scale (PANSS) for schizophrenia.

By S. Kay, A. Fiszbein, L. Opler. 1987

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Informing sequential clinical decision-making through reinforcement learning: an empirical study (2010, methodology): “Throughout this paper, we take as the primary outcome the Positive and Negative Syndrome Scale (PANSS) score (Kay et al. 1987).”
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). (2006, unknown): “Zuclopenthixol 5 2 37 (20-50) Zuclopenthixol decanoate 3 8 358 fortnightly (150-750 fortnightly) SGA arm (n = 109)† Amisulpride 13 10 610 (200-1200) Olanzapine 50 37 15 (5-30)‡ Quetiapine 23 11 450 (200-750) Risperidone 22 13 5 (2-10)”
Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression: A Multimodal, Multisite Machine Learning Analysis (2018, background): “Suchprognostic toolsmay catalyze the development of novel biobehavioral therapies for individualized secondary and tertiary prevention.(4,44-47) In this article, we report on what is to our knowledge the first international effort todevelop such tools for thepredictionof functional outcomes in young”
EEG Frequency Bands in Psychiatric Disorders: A Review of Resting State Studies (2019, methodology): “As well as more conventional DSM/ICD measures, schizophrenia diagnosis and severity was typically assessed using the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) and the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962).”
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders (2016, background): “Trainee psychiatrists should be familiar with the items in the Positive and Negative Symptom Scale (PANSS) (Kay et al., 1987) which forms the basis of assessing the efficacy of antipsychotic medication.”
Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia (2002, methodology): “Severity of positive, negative, or general symptoms measured with the PANSS subscales were not predictive of performance at 1-back, 2-back, or 3-back conditions (r2 0.15, p 0.05 for all correlations).”
Optogenetic investigation of neural circuits underlying brain disease in animal models (2012, background): “Schizophrenia symptoms include disorganized speech and behaviour, as well as hallucinations, delusions and negative symptoms such as impaired social functio”
Assessment of psychiatric symptoms using the SCL-90 (2003, methodology): “It was used as a secondary outcome measure with the rationale of supplementing data received by the PANSS with self-report data.”
Human EEG gamma oscillations in neuropsychiatric disorders. (2005, background): “The schizophrenic symptoms can be divided into positive and negative components depending on whether they also appear in healthy subjects (Kay et al., 1987).”
Decreased language lateralization is characteristic of psychosis, not auditory hallucinations. (2010, methodology): “Furthermore, in the patient group the Positive and Negative Syndrome Scale (PANNS; Kay et al., 1987) was used to assess symptoms.”
Cognitive therapy for the prevention of psychosis in people at ultra-high risk (2004, methodology): “…limited intermittent psychotic symptoms’ BLIPS) or attenuated (subclinical) psychotic symptoms, both of which were defined using an adaptation of the PACE duration and severity criteria (Yung et al, 1996), based on the Positive and Negative Syndrome Scale (PANSS; Kay & Opler, 1987) cut-off scores.”
The brief negative symptom scale: psychometric properties. (2011, methodology): “Principles for design of the BNSS included: (1) that it be concise and feasible for large, multicenter trials; (2) that the 5 domains cited by the Consensus Development Conference be included, with a separate subscale score for each; (3) items that could be assessed in a variety of cultures; (4) sui”
Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 controls via the ENIGMA consortium (2018, background): “PANSS total, positive, and negative symptom severity scores were not significantly correlated with regional cortical surface area for any of the DK atlas regions (Tables S45–S47 in Supplement 1).”